$500,000 Grant from ALS Association and I AM ALS
On June 9, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced a combined grant of $500,000 from the ALS Association and I AM ALS to support an ALS biomarker study utilizing samples and data from the ongoing Phase 3 clinical trial of NurOwn® in ALS patients. The goal of the study is to gain a better understanding of critical biomarkers in the brain and spinal cord that are associated with treatment response to NurOwn®. The combined grant consists of $400,000 from the ALS Association and $100,000 from I AM ALS and is a strong validation of the work being done by BrainStorm in the quest for an effective ALS treatment. Given that this is one of the largest clinical trial collections of cerebrospinal fluid (CSF) biomarkers, the company has agreed to share all data and samples with the ALS community so that the results can be independently verified and hopefully contribute to other ALS research advances.
Author: Canan Schuman, PharmD/PhD
Canan Schumann is Chief Editor for Axxiem and for Axxiem's blog "BiotechOntheWeb". When not writing for Axxiem, Canan works as a Clinical Research Scientist II at the Research and Development Department at Molecular Testing Labs, developing endpoint assays for the detection of infectious disease and cancer. Canan currently resides in Portland, Oregon, where he received his Honors Bachelor of Science (HBS), Doctor of Pharmacy (PharmD.), and his Doctor of Philosophy (Ph.D.) in Biopharmaceutics at Oregon State University.